Opyl reaches key milestone for its clinical trial recruitment platform Opin, shares jump

Opyl’s agreement with CCRM today will provide Opin access to a global network of regenerative medicine companies who are conducting clinical trials.

“Our focus is on creating network alliances with sub-sectors where there is a large volume of trials that require large patient and participant cohorts, have sizable recruitment budgets, and in which we have subject matter expertise and connections within the Opyl team,” explained CEO of Opyl, Michelle Gallaher.

This is only an excerpt taken from an article originally written by Stockhead. Read the full version here.